CLEAN AIR ACT OZONE-DEPLETING SUBSTANCE BANS: INTERIM EXEMPTIONS
This article was originally published in The Gray Sheet
Executive SummaryCLEAN AIR ACT OZONE-DEPLETING SUBSTANCE BANS: INTERIM EXEMPTIONS for "potentially essential" medical products are available, FDA says in a notice published in the Dec. 28 Federal Register. "Because of the impending effective dates" of bans on the sale or distribution of certain "nonessential" products that either release a class I ozone-depleting substance into the environment or contain a class II ozone-depleting substance, FDA says it will "consider granting" interim exemptions "based on the filing of a petition" requesting "essential" status for a product.
You may also be interested in...
A collaboration between Novo and Fauna will look at animal hibernation and genetic sequencing for hints toward novel therapies for obesity. Pfizer will use Insilico’s machine learning technology in target validation.
The introduction of gene therapies has been the highest-profile new modality to reach the market, but new RNA-based therapeutics hold significant potential and could be more accessible for patients. Scrip reviews the leading drug developers in this space.